- Home
- MVSTW vs TGTX Comparison
MVSTW vs TGTX Comparison
Compare MVSTW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVSTW | TGTX |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | United States |
| Employees | 1921 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 5.5B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | MVSTW | TGTX |
|---|---|---|
| Price | $0.16 | $31.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $54.75 |
| AVG Volume (30 Days) | 126.0K | ★ 1.6M |
| Earning Date | 03-14-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | $370,989,000.00 | ★ $531,898,000.00 |
| Revenue This Year | N/A | $87.88 |
| Revenue Next Year | N/A | $48.75 |
| P/E Ratio | ★ N/A | $11.16 |
| Revenue Growth | 39.03 | ★ 100.88 |
| 52 Week Low | $0.35 | $25.28 |
| 52 Week High | $0.44 | $46.48 |
Technical Indicators
Market Signals| Indicator | MVSTW | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 48.42 |
| Support Level | $0.10 | $29.79 |
| Resistance Level | $0.15 | $32.30 |
| Average True Range (ATR) | 0.04 | 1.09 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 42.82 | 61.38 |
Price Performance
Historical ComparisonAbout MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.